
Quarterly report 2023-Q2
added 08-14-2023
Biocept Net Debt 2011-2026 | BIOC
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Biocept
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| -11.2 M | -27 M | -3.6 M | -6.76 M | -1.8 M | 581 K | -1.55 M | -4.59 M | -485 K | 7.11 M | 22.2 M | 13.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 22.2 M | -27 M | -1.16 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Diagnostics research industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
1.18 M | - | -6.23 % | $ 30.6 M | ||
|
Anixa Biosciences
ANIX
|
-1.04 M | $ 3.03 | -2.26 % | $ 98.3 K | ||
|
Akumin
AKU
|
1.21 B | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
-10.9 M | - | -6.19 % | $ 10.5 M | ||
|
Castle Biosciences
CSTL
|
-108 M | $ 39.83 | 1.7 % | $ 1.11 B | ||
|
Brainsway Ltd.
BWAY
|
-6.88 M | $ 23.52 | -2.2 % | $ 99.4 M | ||
|
Burning Rock Biotech Limited
BNR
|
-76 M | $ 34.0 | 0.68 % | $ 366 M | ||
|
Accelerate Diagnostics
AXDX
|
-33.3 M | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
-560 M | $ 102.43 | 0.13 % | $ 19 B | ||
|
Fulgent Genetics
FLGT
|
-53.3 M | $ 26.13 | -0.44 % | $ 790 M | ||
|
BioNano Genomics
BNGO
|
-2.64 M | $ 1.3 | -11.56 % | $ 1.65 M | ||
|
Guardant Health
GH
|
646 M | $ 111.99 | 1.37 % | $ 13.7 B | ||
|
Check-Cap Ltd.
CHEK
|
-11.6 M | - | - | $ 9.42 M | ||
|
Oxford Immunotec Global PLC
OXFD
|
-173 M | - | - | $ 562 M | ||
|
Chembio Diagnostics
CEMI
|
-17.2 M | - | 0.22 % | $ 16.8 M | ||
|
Co-Diagnostics
CODX
|
-11.9 M | - | - | $ 79.8 M | ||
|
Danaher Corporation
DHR
|
13.6 B | $ 218.32 | -0.59 % | $ 160 B | ||
|
DermTech
DMTK
|
-33.6 M | - | -11.32 % | $ 2.94 M | ||
|
Lantheus Holdings
LNTH
|
-346 M | $ 66.61 | -0.1 % | $ 4.61 B | ||
|
Global Cord Blood Corporation
CO
|
-6.07 B | - | - | $ 399 M | ||
|
Fluidigm Corporation
FLDM
|
-5.38 M | - | 1.08 % | $ 308 M | ||
|
Genetic Technologies Limited
GENE
|
-11.1 M | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.35 B | - | 0.12 % | $ 80.1 M | ||
|
PRA Health Sciences, Inc.
PRAH
|
769 M | - | - | $ 10.7 B | ||
|
DexCom
DXCM
|
-487 M | $ 73.22 | -1.05 % | $ 28.3 B | ||
|
NeoGenomics
NEO
|
-23.3 M | $ 11.91 | -3.95 % | $ 1.51 B | ||
|
CareDx, Inc
CDNA
|
-48 M | $ 20.33 | -2.26 % | $ 1.09 B | ||
|
Celcuity
CELC
|
82.8 M | $ 108.09 | -3.59 % | $ 4.26 B | ||
|
DarioHealth Corp.
DRIO
|
-12.1 M | $ 10.14 | -1.55 % | $ 288 M | ||
|
Enzo Biochem
ENZ
|
-51.3 M | - | -8.98 % | $ 14.8 K | ||
|
Personalis
PSNL
|
-48.8 M | $ 9.27 | -7.02 % | $ 549 M | ||
|
Heska Corporation
HSKA
|
-153 M | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-11.2 M | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
-494 M | $ 144.04 | -3.77 % | $ 22.9 B | ||
|
QIAGEN N.V.
QGEN
|
1.31 B | - | - | $ 10.6 B | ||
|
IQVIA Holdings
IQV
|
11.2 B | $ 229.24 | -2.71 % | $ 41.6 B | ||
|
Charles River Laboratories International
CRL
|
2.1 B | $ 208.45 | -1.53 % | $ 10.7 B | ||
|
Thermo Fisher Scientific
TMO
|
27.3 B | $ 575.61 | -2.79 % | $ 220 B | ||
|
Trinity Biotech plc
TRIB
|
55.4 M | $ 0.81 | -7.96 % | $ 61.9 M | ||
|
Twist Bioscience Corporation
TWST
|
-107 M | $ 40.92 | -1.59 % | $ 2.45 B | ||
|
Medpace Holdings
MEDP
|
-520 M | $ 581.54 | -1.94 % | $ 18 B | ||
|
Quest Diagnostics Incorporated
DGX
|
5.24 B | $ 185.97 | 1.99 % | $ 20.6 B | ||
|
Biodesix
BDSX
|
14.5 M | $ 9.61 | -0.57 % | $ 1.25 B | ||
|
Motus GI Holdings
MOTS
|
-3.55 M | - | -34.28 % | $ 263 K | ||
|
Precipio
PRPO
|
-1.18 M | $ 24.39 | 0.54 % | $ 31.7 M | ||
|
Laboratory Corporation of America Holdings
LH
|
4 B | $ 269.91 | 0.04 % | $ 22.6 B | ||
|
Mettler-Toledo International
MTD
|
1.8 B | $ 1 376.67 | -1.16 % | $ 29.2 B | ||
|
ICON Public Limited Company
ICLR
|
4.63 B | $ 179.26 | -3.57 % | $ 14.8 B | ||
|
IDEXX Laboratories
IDXX
|
183 M | $ 673.4 | -0.49 % | $ 55.5 B |